Single-dose, injected flu treatment shows promiseSingle-dose,...
Single-dose, injected flu treatment shows promise A new single-dose, injected drug appears safe and effective at helping ease flu symptoms. Check out this story on thenewsstar.com: http://tnsne.ws/1s1uhzp In this photo, a nurse is administering an intramuscular injection into the left shoulder muscle of a 13-year old boy as his mother looks on.
Mon Sep 08, 2014
HIV and Hepatitis
ICAAC 2014: Single Dose of Flu Drug Peramavir Looks Safe and Effective
A single dose of the investigational neuraminidase inhibitorperamavir administered within 2 days after symptom onset lowered influenza viral load and reduced duration of symptoms including fever, according to study findings presented at the the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC. Peramivir, developed by BioCryst Pharmaceuticals, is a potent injected neuraminidase inhibitor with in vitro activity against all influenza virus subtypes.
Sat Sep 06, 2014
Single-Dose, Injected Flu Treatment Shows Promise
The studies included a total of 427 adults who were given one injection of the drug peramivir or a placebo within 48 hours of the start of flu symptoms. Compared to those given the "dummy" injection, patients who received the drug were symptom-free a median of 22 hours sooner, and fever-free 24 hours sooner, the studies found.
BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting
BioCryst Pharmaceuticals, Inc. today announced trial results related to RAPIVAB , a neuraminidase inhibitor for the treatment of influenza at the Interscience Conference on Antimicrobial Agents & Chemotherapy in Washington, D.C., September 5-9, 2014. "Based on clinical trial data, peramivir is the first neuraminidase inhibitor that has shown to be safe and effective as a single-dose therapy for patients with acute, uncomplicated influenza," said presenting author Richard Whitley, M.D , University of Alabama at Birmingham.
Thu Sep 04, 2014
Biocryst Pharmaceuticals Participates In World Health Organization...
RESEARCH TRIANGLE PARK, N.C., Sept. 4, 2014 -- BioCryst Pharmaceuticals, Inc. today announced its participation in a consultation on potential Ebola therapies and vaccines hosted by the World Health Organization .
Wed Sep 03, 2014
Biocryst Pharmaceuticals To Present At Rodman & Renshaw Conference
BioCryst Pharmaceuticals, Inc. today announced that its executives are scheduled to present a corporate summary and update regarding the Company's development programs at the Rodman & Renshaw 16th Annual Investment Conference in New York on Wednesday, September 10, 2014 at 10:50 a.m. Eastern Time.
Durham's BioCryst defaults on loan after poor sales of flu drug in Japan
BioCryst had expected the default to happen, so some the fallout was already backed in to the share price, which still close at $12.86, near the 52-week high of $14.62, largely because BioCryst is developing a drug that could fight the Ebola virus .
Tue Sep 02, 2014
BioCryst to Present Peramivir Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting
BioCryst Pharmaceuticals, Inc. today announced the presentation of trial results related to intravenous peramivir for the treatment of influenza at the Interscience Conference on Antimicrobial Agents & Chemotherapy in Washington, D.C., September 5-9, 2014.
Fri Aug 29, 2014
Insider Selling: Thomas R. Staab II Sells 10,000 Shares of BioCryst Pharmaceuticals Stock
BioCryst Pharmaceuticals CFO Thomas R. Staab II unloaded 10,000 shares of the stock in a transaction dated Wednesday, August 27th.
Biocryst Pharmaceuticals Expected To Jump Into Ebola Race In A Few Weeks
BioCryst Pharmaceuticals, Inc. today announced that the National Institute of Allergy and Infectious Diseases has awarded a contract modification for an additional $2.4 million to BioCryst to conduct a dose ranging efficacy study of an intramuscular formulation of BCX4430 in non-human primates as a treatment for Ebola virus disease.
Local Tech Wire
US to begin tests of GSK's Ebola vaccine next week
The National Institutes of Health announced Thursday that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline .
Wed Aug 27, 2014
Glaxo's Ebola Vaccine to Be Tested for Safety in Humans
U.S. scientists will begin enrolling patients as soon as next week in clinical safety trials of GlaxoSmithKline Plc 's experimental Ebola vaccine as the death toll from the disease rises in West Africa.
Tue Aug 26, 2014
Use Options For a Chance To Buy BCRX at a 59% Discount
Options For Income is a contributor page created by the editors of Stock Options Channel, a stock options research Website.
Fri Aug 22, 2014
BioCryst Pharmaceuticals Receives Consensus Rating of "Buy" from Analysts
BioCryst Pharmaceuticals has earned a consensus rating of "Buy" from the twelve brokerages that are covering the company, Stock Ratings Network reports .
Tue Aug 19, 2014
Local Tech Wire
$4.1M federal grant could put BioCryst in Ebola fight - next time
It was not only a $4.1 million influx of additional federal research money to Durham drug development company BioCryst Pharmaceuticals.
Mon Aug 18, 2014
BioCryst Pharmaceuticals Given Average Rating of "Buy" by Analysts
BioCryst Pharmaceuticals has received a consensus rating of "Buy" from the twelve analysts that are covering the stock, Stock Ratings Network reports .
Duke: Using experimental drug in Ebola outbreak could 'prove disastrous'
It's a debate federal regulators and drug companies have all the time. Should a company with an experimental drug give it to people in need to potentially save their lives, or should regulators make sure the drug is safe before it does any more harm? It's a question that seems to always result in a lose-lose situation.